Melissa Raven (@psychepi) profile picture

Psychiatric epidemiologist policy analyst Critic of dodgy claims/bandwagons/propaganda/conflicts of interest. JSBachtragic Klavierschülerin Ambulophile Aviphile

Joined September 2011
Photo by Melissa Raven (@psychepi)Photo by Melissa Raven (@psychepi)Photo by Melissa Raven (@psychepi)Photo by Melissa Raven (@psychepi)
Melissa Raven retweeted
Hilary Mantel went to her doctor at 19 with pain in her legs and her belly, and within a couple of years she was in a psychiatric clinic, on antipsychotics, being advised to stop writing. She was a law student from a mill town in Derbyshire, the first in her family at university, sharp and ambitious. The pain had been coming every month since she was 11. Her GP could find nothing, decided it was nerves, and prescribed antidepressants. When those didn't work she was referred to a psychiatrist. His view was that the trouble was ambition. A girl of her background was straining after too much. He gave her Valium, which made her rage, and when she raged he gave her an antipsychotic. The antipsychotic gave her akathisia, a side effect in which the body cannot keep still and the mind fills with a horror that has no object. She paced, could not sit, could not read. She said afterwards it was the worst thing that ever happened to her. On the ward it was written down as her illness getting worse, and the dose was reviewed accordingly. The more she said the problem was in her body, the surer they became it was in her head. She was told that writing was bad for her. She got herself off the drugs and out of the clinic. A few years later, living in Botswana, she sat down with a medical textbook and worked out the diagnosis herself. She had endometriosis: tissue like the lining of the womb growing through her pelvis and bleeding every month with nowhere to go. By the time a London surgeon opened her up to confirm it she was 27, and the disease had got so far that he took out her womb, her ovaries and sections of her bowel and bladder. She woke up in the menopause. The hormones she was given afterwards changed her body beyond recognition. Then she wrote Wolf Hall and Bring Up the Bodies and became the first woman to win the Booker Prize twice. It took eight years, six doctors and a psychiatric admission to diagnose one of the commonest conditions in women. In the end it was done by the patient, in Africa, with a library book.
181
1,654
84
6,854
132,980
Note to all those who won't acknowledge they were wrong during Covid because they don't want to look stupid: look at Matt Ridley - he doesn't look stupid, he looks all the more noble for saying plainly he was misled. I'm in admiration.
Full text of article: Jay Bhattacharya, head of the National Institutes of Health, has written to Nature Medicine journal demanding a “formal, independent investigation” into why a key scientific paper misled the world about the virus causing Covid, and concealed the contributions made by three senior scientists to commissioning, reviewing and editing the paper. In a career as a science writer that spans more than four decades, I have never seen an alleged case of scientific malpractice as influential. Like many others I have called for the paper to be retracted. Twice, the editor of the journal, Joao Monteiro, has been sent letters from numerous leading scientists demanding an investigation or retraction of the misleading paper. He has ignored us. I know the paper entitled “Proximal Origin of SARS-CoV-2” was misleading because I was among those misled. At the time I sat on the science and technology select committee of the House of Lords and we were conducting an inquiry to try to understand this new virus threatening all our lives. The possibility that it had been accidentally released from a laboratory, if true, would have significant implications for the public-health response: a virus marinaded in human tissues in a laboratory for weeks would be far more infectious than one newly arrived from bats. Parliamentary colleagues were asking me what I thought. To my shame, I told them a lab leak could be ruled out. I did so based almost entirely on the authority of this one paper. That very phrase “ruled out” appeared in the press announcement of the paper from the institution where the lead author, Kristian Andersen, worked. The article itself left no room for doubt: “we do not believe that any type of laboratory based scenario is plausible… our analyses clearly show that SARS-CoV-2 is not a laboratory construct.” That these words appeared in Nature Medicine gave them a stamp of authority, or so I believed. The paper was subsequently viewed millions of times and cited in thousands of academic papers. The journal and the authors of the paper therefore had a special responsibility not to allow themselves to be misled. Yet we now know that Proximal Origin’s arguments were flawed and released Slack messages and emails show several of its authors were expressing exactly the opposite opinion in private both before, during and after publication. They still thought a lab leak was “friggin likely”, in the words of Andersen. Worse than all that, congressional investigations have uncovered records strongly indicating that three of the most senior medical scientists in the world, Francis Collins (Bhattacharya’s predecessor as head of the National Institutes of Health), Anthony Fauci (head of National Institute for Allergy and Infectious Diseases) and Jeremy Farrar (head of the Wellcome Trust) had not only seen the paper before publication, but – according to a House Select Subcommittee report – had prompted its authors to write it in the first place, had reviewed it and even suggested alterations in wording. Fauci referred to the paper from the White House podium, giving no hint of his own role in it. These men were heads of the bodies that funded the scientists’ work, yet they were not listed as co authors or acknowledged in the paper, despite the journal’s stated policy that authors disclose any funder’s “involvement in the conceptualisation, design, data collection, analysis, and preparation of the paper”. Farrar even suggested a change of wording to strengthen its conclusion: from “unlikely” to “improbable”. Why was he not acknowledged? Robert Garry, one of the authors, wrote to his colleagues: “Jeremy has been an amazing leader – should be author.” Ed Holmes, another author, replied: “I agree, and I offered, but he wants to remain independent.” As we wrote to the journal editor in 2024: “This omission of a significant role played by the head of a funding agency, allegedly to maintain his ‘independence’, represents a serious breach of publishing ethics that completely undermines the credibility of the journal and calls into question the motivation behind the paper.” Answer came there none. It should infuriate the journal’s editor that the paper appears to have been commissioned, designed and intended to shut down all debate about a possible laboratory origin of the most destructive pandemic in a century despite going directly against its authors’ own opinions. For the sake of science’s integrity the journal must act on Dr Bhattacharya’s letter.
40
83
6
811
72,046
Melissa Raven retweeted
"When You Can’t Win on the Science, Attack the Scientist - Jack Goulder, @joannamoncrieff and the politics of personality." Out now 👇
🤖 Made with AI
1
8
1
13
686
Melissa Raven retweeted
50 yrs intense brain/genetics research failed to find any diagnostic biomarkers in psychiatry. Suggestion that blood tests will diagnose psych disorders seems like triumph of naive hope over painful (& expensive) experience. How about instead spending more money on caring for suffering patients.
19
57
3
216
9,925
Melissa Raven retweeted
NEW STUDY: Sertraline, Fluoxetine, & Escitalopram impact the developing fetal mouse brain. "The fetal brain exhibited relatively consistent susceptibility across exposure groups." "Prenatal SSRIs induce serotonergic disruption." bioengineer.org/prenatal-exp…
2
21
2
60
2,703
ADHD & ASD were most frequently identified as self-diagnosed or desired...[by people] commonly described as female, highly educated, & strongly engaged in online activities...[this was explained] mainly in terms of relief from guilt, identity affirmation, and social recognition. pubmed.ncbi.nlm.nih.gov/4155…
14
52
13
320
17,459
Very useful summary - especially so because it is in a paediatric journal.
Kudos to Contemporary Pediatrics for highlighting these points in this new article (link below) about stopping antidepressants in young people- something I have firsthand experience of and could've done with doctors/psychiatrists knowing this decades ago (and explaining it to me at the point of prescribing). I'm presuming it focuses on fluoxetine because it's the one that (at least here in the UK) is approved for use in children and young people - although the author is based in the US so I suspect this is from a US perspective. As well as pointing to emerging evidence supporting hyperbolic tapering, it highlights the following three points, the latter two of which are relevant to ALL SSRIs and SNRIs: "- Fluoxetine is not "self-tapering": withdrawal can occur despite its long half-life, and onset may be delayed weeks to months after discontinuation. - New, unfamiliar, or unusually intense emotional symptoms accompanied by physical or sensory symptoms after discontinuation point toward withdrawal rather than relapse. - Long-term treatment and irregular adherence raise withdrawal risk, and mistaking withdrawal for relapse can lead to unnecessary medication exposure."
1
9
18
833
Melissa Raven retweeted
Sam says it best about antidepressant withdrawal: "People who were prescribed these drugs in good faith are now having to educate themselves in pharmacology just to escape them without becoming seriously unwell. It is an extraordinary failure of patient care, informed consent and medical responsibility."
🧵 1/ Today I’ve started tapering from 3 mg of sertraline, having held this dose for over two years. I’m approaching four years of protracted withdrawal after being taken off 150 mg of sertraline following long term use. What followed was a succession of drug switches, high dose reinstatements with adverse reactions and dosage changes after my withdrawal symptoms were misdiagnosed as a mood disorder, FND and potentially bipolar disorder, amongst other things. Unfortunately, reinstating 3 mg of sertraline did nothing to stabilise my system. Despite remaining on this dose for over two years, I continue to experience significant neurological and physical symptoms. I’m now questioning, with the help of a knowledgable psychiatrist and clinic, whether continued exposure to sertraline could actually be contributing to or aggravating my symptoms, rather than providing any meaningful stabilisation. I also remain on 25 mg of quetiapine, originally prescribed to help with sleep during sertraline withdrawal, which may be contributing to some of the problems too. My main concern is the possibility of kindling and progressive nervous system sensitisation. Following repeated rapid tapers, reinstatements and switches between psychiatric drugs, my nervous system has become increasingly sensitive and reactive to pharmacological changes. Kindling is a term used to describe a process in which repeated episodes of stimulation or disruption can produce progressively greater responses to subsequent exposures. In the context of psychiatric drug withdrawal, the hypothesis is that repeated withdrawal episodes and drug changes may leave some individuals increasingly vulnerable to subsequent disruptions. The precise mechanisms in antidepressant withdrawal are not yet established and this remains an area requiring considerably more research. One possible explanation involves neuroadaptation. When someone takes an SSRI over an extended period, the brain adapts to the drug’s effects on serotonin signalling. Sertraline inhibits the serotonin transporter (SERT), reducing the reuptake of serotonin from the synaptic space. Over time, the nervous system makes compensatory adjustments to function in the presence of that ongoing pharmacological effect. When the drug is rapidly reduced or removed, those adaptations do not necessarily reverse at the same speed, potentially creating a period of physiological instability. There is also an important pharmacological reason why I cannot simply stop taking 3 mg of sertraline because it appears to be a very small dose. Research using PET and SPECT brain imaging has demonstrated that the relationship between antidepressant dose and serotonin transporter occupancy is hyperbolic rather than linear. In other words, occupancy increases rapidly at lower doses before gradually approaching a plateau at higher therapeutic doses. A model based estimate published using this research suggests that approximately 2.2 mg of sertraline may produce around 20% SERT occupancy, while 5.9 mg may produce around 40%. This would put my 3 mg dose somewhere in the region of 20 - 25%, although this is an extrapolation rather than a direct measurement at my dose. This is significant because 3 mg is not necessarily pharmacologically insignificant. Even at this low dose, sertraline may still be occupying a meaningful proportion of serotonin transporters. Reducing it too quickly could therefore produce further pharmacological changes that my already sensitive system may struggle to accommodate. My symptoms currently include bouts of akathisia, muscles in my legs tightening and cramping as though locked in a vice, intense head pressure and electrical sensations throughout my body, almost as though electrical cables have been severed, alongside numerous other neurological and sensory disturbances. I’m concerned that these symptoms may be related to previous withdrawal, ongoing drug exposure or a combination of both. I don’t …
7
22
76
2,048
Good to see a portion of the misrepresentations made by Jack addressed here. It is a pity so much energy needs to be expended on such ideological exercises (Jack's) which distract from the more important question of what we need to do to address such widespread and long-term use of medications with marginal benefits and significant harms.
2
15
54
1,419
Have you ever wondered why your doctor doesn't listen to your report of an adverse drug effect? Does your doctor want you to suffer? No, your doctor just wants you to shut up & take your medicine.
Prof @JamesStein18 Is Sensitive to Medicine - Just Like Everyone Else: But most people cannot be more sensitive than most people jamesstein18.substack.com/p/…
1
6
18
458
Melissa Raven retweeted
I credit Dr. Lesaca for addressing the issue of antidepressants & pregnancy in this article. He is correct that none of the antidepressants are "proven safe" in pregnancy. Some concerns I have are: #1. There is no mention of the increased risk of postpartum hemorrhage (PPH) with SSRIs. PPH is a leading cause of maternal morbidity & mortality. This risk is on the SSRI labels and must be reviewed with patients. #2. There is no mention of the long-term effects on the developing fetal brain. We now have thirteen (13) consecutive MRI studies showing evidence of altered brain development with SSRI exposure. And we also have numerous studies showing differences in language and motor skills, school performance, mental health, and neurobehavioral disorders. #3. There is no mention of the risks of pregnancy loss and low birth weight, associations which have been demonstrated in many animal and human studies. #4. The article suggests that "untreated maternal illness" increases pregnancy complications. It is true that some studies show that depression is associated with some obstetrical complications. But the use of the term "untreated maternal illness" suggests that treating women with antidepressants has been proven to improve pregnancy outcomes. This is not the case. In fact, the majority of studies in this area show that the antidepressant-treated women have worse (not better) obstetrical outcomes (eg more preterm birth, low birth weight, & preeclampsia.) I credit him for recognizing that antidepressants cannot be said to be "proven safe" in pregnancy. But proper patient counseling requires us to go beyond this and to fully explain the risks (and benefits and alternatives) to patients. kevinmd.com/2026/11/which-an…
3
24
1
34
1,451
I've been invited to participate in this year's Maudsley Debate, supporting the notion: 'This House Believes that Biological Psychiatry has Failed to Deliver Significant Benefit for Patients'. - Attendance is free - reserve your place below 👇 eventbrite.co.uk/e/65th-maud…
10
34
4
102
7,889
Fantastic to see awareness of psychiatric drug withdrawal and safe deprescribing to Greece. Greek citizens are very lucky to have @GKasioumi as a fierce champion of this work. Again, how much of an indictment it is of the status quo that patients harmed by drugs have to take on the effort to educate clinicians about the harm they have done.
On November 7, we held the 1st SafeMeds Hellas Forum on Antidepressant Withdrawal in Greece, bringing together distinguished scientists, healthcare professionals, and people with lived experience. 📊 More than 6,500 page views and 365 registrations! My deepest gratitude to @markhoro for his invaluable scientific contribution, trust, and generous support of this initiative. Sincere thanks to all our speakers, moderators, and participants for contributing to this important dialogue on antidepressant withdrawal, patient safety, and safer clinical practices. #SafeMedsHellas #AntidepressantWithdrawal #MarkHorowitz #Deprescribing #PatientSafety
1
18
1
49
1,410
Piece on diagnosis acting as an 'identity intervention,’ influencing 'the self-concept, expectations, and life story of a person with mental health issues in a potentially harmful way that goes beyond the descriptive function of the diagnostic label'. journals.plos.org/mentalheal…
12
30
4
99
5,253
Thank you Daniel. This is why I wrote Chemically Imbalanced, because this myth has fundamentally shaped people's views and decisions about antidepressants. The pharmaceutical industry knew it would and the psychiatric profession played along. People need to know the truth.
The Chemical Imbalance Myth: What Jack Goulder Gets Wrong I've read the recent Substack article by Jack Goulder entitled Merchants of Psychiatric Doubt and the subsequent exchanges with Dr Horowitz. First of all, I think it was poor judgment of Goulder to misquote Horowitz and Moncrieff, particularly when that quotation was central to his accusation that they had misrepresented their research. More fundamentally, though I think his dismissal of Horowitz's argument as "semantic somersaults" overlooks an important historical distinction. Contrary to the impression given in the article, the chemical imbalance theory was not simply a marketing narrative seized upon by drug companies. It was actively promoted and legitimised by influential figures within institutional medicine, particularly psychiatry. Until relatively recently, the NHS reproduced versions of this explanation on its websites, and as recently as 2025, Rebecca Brendel, a former president of the American Psychiatric Association, was publicly linking low serotonin with depression in the Washington Post. Psychiatry itself helped establish the credibility of this narrative, and the profession's role in promoting it deserves serious historical scrutiny. This matters because the chemical imbalance theory was not merely an abstract scientific hypothesis. It fundamentally shaped how depression was understood by the public, how SSRIs were presented to patients, and potentially how people made decisions about treatment. Millions of people were given the impression, by psychiatrists, GPs and medical journalism, that SSRIs corrected an underlying chemical deficiency. That is a very different proposition from telling patients that these drugs alter brain chemistry in ways we do not fully understand, that their average benefits over placebo are relatively modest, and that they carry risks. The chemical imbalance narrative also had important implications for long term prescribing. If patients believed they had an underlying serotonin deficiency, it was entirely reasonable for them to conclude that they might need medication indefinitely, just as someone with diabetes might require insulin. Whether and to what extent that belief contributed to long term prescribing deserves investigation, but it is hardly a trivial question. In other words, the theory that depression results from low serotonin played an important role in legitimising the widespread use of SSRIs, including their long term use. We now know that this explanation was not supported by the evidence. It is therefore entirely reasonable to say that research challenging the serotonin hypothesis also calls into question one of the principal historical rationales offered for prescribing these drugs. It is true that this is not the same as claiming that SSRIs have been demonstrated to be ineffective. Whether a drug produces a clinically meaningful benefit is a separate empirical question from whether it corrects the biological abnormality it was purportedly prescribed to treat. The is a substantive difference not a semantic one. It also raises important questions about informed consent. Patients are entitled to accurate explanations of why a treatment is being recommended, not simply evidence that it may produce some benefit. What I find particularly striking about the article is that Goulder devotes considerable attention to the philosophical commitments of psychiatry's critics, while giving comparatively little scrutiny to the professional and institutional commitments that helped sustain the chemical imbalance narrative for decades. If his concern is how prior beliefs and institutional interests shape the interpretation and communication of scientific evidence, surely that scrutiny should apply equally to mainstream psychiatry. One can reasonably argue that the serotonin hypothesis has no direct bearing on the evidence from antidepressant efficacy trials. But it does not follow that discrediting the hypothesis has no bearing on the historical justification for prescribing these medications, or on the decisions patients made after being told they suffered from a chemical imbalance. To characterise that distinction as "semantic" is, I think, to fundamentally miss the point of why setting the record straight about the chemical imbalance story matters so much.
1
17
78
2,299
Melissa Raven retweeted
In this NEW Study, SSRI-exposed newborns had a nearly FIVE-fold increased risk of an Apgar score < 7. The authors write: "A possible explanation is the direct effect of SSRIs on the development of the fetal brain."
NEW Study: -SSRI users were more likely to have neonates with head circumference < 35 cm & had nearly FIVE-fold higher odds of 5 min Apgar score < 7. -SSRI users also had ⬆️ rates of postpartum hemorrhage & early-term birth. -Rates of prenatal SSRI use increased roughly NINE-fold in Sweden from 2005 to 2015. tandfonline.com/doi/full/10.…
4
16
44
1,170
Thank you, Mark, for correcting the record and making it clear that we did NOT misrepresent our research, as accused. I have requested that the Journal that published this paper issues a correction too.
Jack has not permitted comments to be put on his blog so I’ll post this here. Many of the points in his blog are false. He has latterly corrected the quotation from our press release after I emailed him (although he does not disclose this was the reason for his correction). As he now acknowledges, we did not say what he had quoted us as saying and he has now corrected the quotation to say “this research calls into question reasonsfor the use of antidepressants.” Of course our paper calls into question the main rationale given to patients for prescribing these drugs – of course it calls the ‘reasons’ into question. He and others may wish to argue that the drugs are prescribed because they are effective (discussed at length elsewhere) but the rationale presented to many patients was (and is) false. Naturally, if it were found that Hashimoto’s disease was not caused by low thyroid hormones it would throw into question the rationale for prescribing thyroid hormones. It would throw into relief questions about long term harms and benefits of such a treatment that would not be raised if the treatment was acting in the self-evidently sensible manner of correcting a hormonal deficit. His central accusation – and the central point of his published article – is that we misleadingly presented our review regarding the aetiology of depression as showing that antidepressants are ineffective. We did not such thing. Jack could find no such quote in our press release so he fudged it. (I believe this is the polite euphemism). Of course such a finding about aetiology invites reflection on the efficacy of the drugs and so naturally we discussed this in the Conversation piece - our comments in this piece are all supported by evidence. His statement about the Nordic Cochrane is also false. Nordic Cochrane moved from Righospitalet in Copenhagen to the University of Southern Denmark in Odense where it merged with the Centre for Evidence-Based Medicine and was renamed to Cochrane Denmark. It still functions today and houses the Cochrane Bias Methods Group which advises Cochrane : www2.cochrane.dk/ He is performing quite some somersaults, slinging mud from unrelated comments made by Peter Breggin, and Peter Gotzsche, to avoid reading an article published in the BMJ Open. An article I would still encourage him and other to read so that they become aware of the substantive criticisms of Cipriani’s meta-analysis rather than assuming the solidity of claims made about antidepressant efficacy: bmjopen.bmj.com/content/9/6/… I expect that after correcting his recent blog he will also correct his original blog on Awais’ website (where he falsely says: “a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) and his academic paper were he makes the same false claim (“a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) as he has now acknowledged that these claims are false. I would like to be notified when these corrections are made.
1
7
51
2,055
Melissa Raven retweeted
Replying to @dsowens17
I do struggle to understand the tenacity with which psychiatry clings to antidepressants. They just…aren’t very effective for most people. The risk/benefit ratio is all risk and no benefit in most cases. Time to pack up and move on surely? Instead, having lost the argument on the evidence, Goulder and co misrepresent and take swipes at the perceived politics of researchers they disagree with. It’s very frustrating.
8
8
1
56
7,751
Melissa Raven retweeted
The Chemical Imbalance Myth: What Jack Goulder Gets Wrong I've read the recent Substack article by Jack Goulder entitled Merchants of Psychiatric Doubt and the subsequent exchanges with Dr Horowitz. First of all, I think it was poor judgment of Goulder to misquote Horowitz and Moncrieff, particularly when that quotation was central to his accusation that they had misrepresented their research. More fundamentally, though I think his dismissal of Horowitz's argument as "semantic somersaults" overlooks an important historical distinction. Contrary to the impression given in the article, the chemical imbalance theory was not simply a marketing narrative seized upon by drug companies. It was actively promoted and legitimised by influential figures within institutional medicine, particularly psychiatry. Until relatively recently, the NHS reproduced versions of this explanation on its websites, and as recently as 2025, Rebecca Brendel, a former president of the American Psychiatric Association, was publicly linking low serotonin with depression in the Washington Post. Psychiatry itself helped establish the credibility of this narrative, and the profession's role in promoting it deserves serious historical scrutiny. This matters because the chemical imbalance theory was not merely an abstract scientific hypothesis. It fundamentally shaped how depression was understood by the public, how SSRIs were presented to patients, and potentially how people made decisions about treatment. Millions of people were given the impression, by psychiatrists, GPs and medical journalism, that SSRIs corrected an underlying chemical deficiency. That is a very different proposition from telling patients that these drugs alter brain chemistry in ways we do not fully understand, that their average benefits over placebo are relatively modest, and that they carry risks. The chemical imbalance narrative also had important implications for long term prescribing. If patients believed they had an underlying serotonin deficiency, it was entirely reasonable for them to conclude that they might need medication indefinitely, just as someone with diabetes might require insulin. Whether and to what extent that belief contributed to long term prescribing deserves investigation, but it is hardly a trivial question. In other words, the theory that depression results from low serotonin played an important role in legitimising the widespread use of SSRIs, including their long term use. We now know that this explanation was not supported by the evidence. It is therefore entirely reasonable to say that research challenging the serotonin hypothesis also calls into question one of the principal historical rationales offered for prescribing these drugs. It is true that this is not the same as claiming that SSRIs have been demonstrated to be ineffective. Whether a drug produces a clinically meaningful benefit is a separate empirical question from whether it corrects the biological abnormality it was purportedly prescribed to treat. The is a substantive difference not a semantic one. It also raises important questions about informed consent. Patients are entitled to accurate explanations of why a treatment is being recommended, not simply evidence that it may produce some benefit. What I find particularly striking about the article is that Goulder devotes considerable attention to the philosophical commitments of psychiatry's critics, while giving comparatively little scrutiny to the professional and institutional commitments that helped sustain the chemical imbalance narrative for decades. If his concern is how prior beliefs and institutional interests shape the interpretation and communication of scientific evidence, surely that scrutiny should apply equally to mainstream psychiatry. One can reasonably argue that the serotonin hypothesis has no direct bearing on the evidence from antidepressant efficacy trials. But it does not follow that discrediting the hypothesis has no bearing on the historical justification for prescribing these medications, or on the decisions patients made after being told they suffered from a chemical imbalance. To characterise that distinction as "semantic" is, I think, to fundamentally miss the point of why setting the record straight about the chemical imbalance story matters so much.
5
22
3
59
4,922